SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-167931
Filing Date
2022-06-06
Accepted
2022-06-06 08:07:01
Documents
14
Period of Report
2022-06-06
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d288634d8k.htm   iXBRL 8-K 29399
2 EX-99.1 d288634dex991.htm EX-99.1 20959
6 GRAPHIC g288634dsp5.jpg GRAPHIC 11677
  Complete submission text file 0001193125-22-167931.txt   192820

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mrtx-20220606.xsd EX-101.SCH 2841
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrtx-20220606_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrtx-20220606_pre.xml EX-101.PRE 10802
8 EXTRACTED XBRL INSTANCE DOCUMENT d288634d8k_htm.xml XML 3204
Mailing Address 3545 CRAY COURT SAN DIEGO CA 92121
Business Address 3545 CRAY COURT SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35921 | Film No.: 22996747
SIC: 2834 Pharmaceutical Preparations